USA flag logo/image

An Official Website of the United States Government

Technologies to Defeat Improvised Explosive Devices (IED's)

Award Information

Agency:
Department of Defense
Branch:
Navy
Award ID:
70346
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
N042-901-0443
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
NANOTHERAPEUTICS, INC.
13859 Progress Blvd. ALACHUA, FL -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Technologies to Defeat Improvised Explosive Devices (IED's)
Agency / Branch: DOD / NAVY
Contract: N00014-04-M-0381
Award Amount: $99,745.00
 

Abstract:

In this Phase I SBIR Proposal, Nanotherapeutics, Inc. proposes to demonstrate the improved proximity detection of hexamethylene triperoxidediamine (HMTD) and triacetone triperoxide (TATP) explosives using its proprietary NanobreathTM preconcentrator and 4-SAW array. The NanobreathTM 4-SAW Array, a novel, portable, rapid gas chromotography (GC) system, currently being developed for medical testing and diagnosis, will be evaluated for the rapid detection of Improvised Explosive Devices (IED's) at safe distances. While most conventional explosives detectors rely on the presence of nitrogen groups in the explosive molecule to obtain a positive response, non-nitrogen containing HMTD and TATP peroxide explosives present a serious challenge to detection and neutralization by counter-terrorism and security forces. Nanotherapeutics proposes to (1) evaluate different concentrations of HMTD and TATP in ambient air, (2) evaluate different preconcentrator adsorbant materials and air collection volumes for proximity sampling, and (3) evaluate different chemoselective polymer coatings on surface acoustic wave (SAW) sensors to measure the linear response range and limit of detection (LOD). It is proposed to demonstrate the feasibility of the NanobreathTM system for improved proximity detection in the Phase I Project towards the development of a robust commercializable explosive detection system in the Phase II Project.

Principal Investigator:

James Talton
President and CEO
3864629663
jtalt@nanotherapeutics.com

Business Contact:

James Talton
President and CEO
3864629663
jtalt@nanotherapeutics.com
Small Business Information at Submission:

NANOTHERAPEUTICS, INC.
12085 Research Dr Ste N, Suite N Alachua, FL 32615

EIN/Tax ID: 593615370
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No